极早产儿脑近红外光谱监测与常规治疗对比:SafeBoosC随机临床III期试验方案
SafeBoosC III是一项研究者发起的跨国随机实用III期临床试验,计划纳入1600例胎龄低于28周的极早产儿,1:1随机分为脑NIRS监测指导治疗组与常规治疗组。主要结局为36周矫正胎龄时死亡或严重脑损伤的复合结局,旨在检测22%的相对风险差异。
要点
- 极早产儿(胎龄<28周)随机接受脑NIRS监测指导治疗或常规治疗。
- 主要结局为36周矫正胎龄时死亡或严重脑损伤的复合结局。
- 计划随机1600例以检测22%的相对风险差异。
核心结论
- 基于脑NIRS氧饱和度监测的治疗可能降低极早产儿死亡或严重脑损伤生存的风险,但需本试验验证。
研究设计与样本
- SafeBoosC III为研究者发起的跨国随机实用III期临床试验,计划随机1600例胎龄低于28周的极早产儿,1:1分为实验组与对照组。
关键数值与推荐
- 纳入标准为胎龄低于28周且获父母知情同意(或采用选择退出/延迟同意)。
- 排除标准包括无父母知情同意、决定不提供全面生命支持、出生后6小时内无法启动脑NIRS血氧监测。
- 实验组在生后72小时内接受脑NIRS监测,脑缺氧按循证治疗指南处理;对照组不监测,接受常规治疗。
- 主要结局为36周矫正胎龄前系列颅脑超声发现的死亡或严重脑损伤复合结局,严重脑损伤由盲法评估。
- 计划随机1600例以检测实验组与对照组之间22%的相对风险差异。
临床怎么用
- 若试验证明有效,脑NIRS监测指导治疗可能成为极早产儿降低死亡或严重脑损伤风险的临床策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cerebral oxygenation monitoring may reduce the risk of death and neurologic complications in extremely preterm infants, but no such effects have yet been demonstrated in preterm infants in sufficiently powered randomised clinical trials. The objective of the SafeBoosC III trial is to investigate the benefits and harms of treatment based on near-infrared spectroscopy (NIRS) monitoring compared with treatment as usual for extremely preterm infants. METHODS/DESIGN: SafeBoosC III is an investigator-initiated, multinational, randomised, pragmatic phase III clinical trial. Inclusion criteria will be infants born below 28 weeks postmenstrual age and parental informed consent (unless the site is using 'opt-out' or deferred consent). Exclusion criteria will be no parental informed consent (or if 'opt-out' is used, lack of a record that clinical staff have explained the trial and the 'opt-out' consent process to parents and/or a record of the parents' decision to opt-out in the infant's clinical file); decision not to provide full life support; and no possibility to initiate cerebral NIRS oximetry within 6 h after birth. Participants will be randomised 1:1 into either the experimental or control group. Participants in the experimental group will be monitored during the first 72 h of life with a cerebral NIRS oximeter. Cerebral hypoxia will be treated according to an evidence-based treatment guideline. Participants in the control group will not undergo cerebral oxygenation monitoring and will receive treatment as usual. Each participant will be followed up at 36 weeks postmenstrual age. The primary outcome will be a composite of either death or severe brain injury detected on any of the serial cranial ultrasound scans that are routinely performed in these infants up to 36 weeks postmenstrual age. Severe brain injury will be assessed by a person blinded to group allocation. To detect a 22% relative risk difference between the experimental and control group, we intend to randomise a cohort of 1600 infants. DISCUSSION: Treatment guided by cerebral NIRS oximetry has the potential to decrease the risk of death or survival with severe brain injury in preterm infants. There is an urgent need to assess the clinical effects of NIRS monitoring among preterm neonates. TRIAL REGISTRATION: ClinicalTrial.gov, NCT03770741. Registered 10 December 2018.
引用
- Hansen ML, Pellicer A, Gluud C, et al. Cerebral near-infrared spectroscopy monitoring versus treatment as usual for extremely preterm infants: a protocol for the SafeBoosC randomised clinical phase III trial. Trials. 2019. PMID: 31888764. doi:10.1186/s13063-019-3955-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。